GLP-1 Prescriptions Without Insurance: Your Complete Options Guide

Brand-name GLP-1 medications like Wegovy and Zepbound carry list prices of $1,000–$1,350 per month. Without insurance coverage, that's $12,000–$16,000 per year — which puts these medications out of reach for most people paying out of pocket.

But "without insurance" doesn't mean without options. The compounded medication market, manufacturer discount programs, and alternative access pathways have created legitimate routes to GLP-1 therapy at a fraction of the brand-name cost.

Option 1: Compounded GLP-1 Medications

Compounded versions of semaglutide and tirzepatide are produced by 503A and 503B-registered pharmacies and prescribed through telehealth providers. These are not generic medications — they're individually compounded from the same active pharmaceutical ingredients.

Compounded medications are not FDA-approved in the same way brand-name drugs are. They undergo a different regulatory pathway. However, they offer the same active ingredients at significantly lower cost, and they've become the primary access point for uninsured patients.

Providers with the strongest value for cash-pay patients

Option 2: Brand-Name Manufacturer Programs

Both Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) offer savings programs for eligible patients:

Novo Nordisk's NovoCare program currently offers brand-name oral Wegovy at $149/mo for the 1.5mg and 4mg doses through August 2026. This promotional pricing makes brand-name access surprisingly competitive with compounded options.

Eli Lilly's Zepbound savings card can reduce costs for commercially insured patients, though cash-pay patients without any insurance may have fewer options.

Brand-name option through telehealth

Option 3: Clinical Trials

ClinicalTrials.gov lists hundreds of active GLP-1 studies recruiting participants. Enrollment in a clinical trial can provide free medication and medical monitoring, though you may receive a placebo in randomized studies. Search for semaglutide or tirzepatide trials in your area at clinicaltrials.gov.

What to Watch: FDA Compounding Regulation

The FDA proposed removing semaglutide and tirzepatide from the drug shortage bulks list on April 30, 2026, with public comments due by June 29, 2026. If this proposal is finalized, compounding pharmacies may lose authorization to produce these medications. This could significantly impact the affordability equation for uninsured patients.

For now, compounded options remain available and legal. But patients who are considering this route may want to start sooner rather than later given the regulatory uncertainty.

The Bottom Line

GLP-1 medications without insurance are expensive at brand-name retail prices, but accessible through compounded alternatives. Monthly costs of $130–$300 for compounded semaglutide represent a 75–90% savings compared to brand-name Wegovy. Flat-rate providers like Oak Longevity and competitive six-month plans from Yucca Health offer the best long-term value for cash-pay patients.